Portola raises $89 million to go it alone with betrixaban
This article was originally published in Scrip
Executive Summary
Portola Pharmaceuticals, a privately-held venture capital-backed company developing therapeutics for cardiovascular and immune diseases, has raised $89 million from new and existing investors to fund Phase III development of its blood thinner, betrixaban, and to develop a companion antidote product. The product was returned to Portola after Merck ended a collaboration in March.